Highlights Regeneron Pharmaceuticals, Inc.

Equities

REGN

US75886F1075

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2026-04-17 pm EDT			5-day change	1st Jan Change
750.57 ^USD	+0.61%		+0.23%	-2.76%

Apr. 13	Regeneron Pharmaceuticals, Inc. and Telix Pharmaceuticals Limited Announce Strategic Radiopharma Collaboration	CI
Apr. 13	Regeneron, Telix Enter Radiopharma Collaboration; Telix Shares Up Pre-Bell	MT

Highlights

Apr. 13	Regeneron Pharmaceuticals, Inc. and Telix Pharmaceuticals Limited Announce Strategic Radiopharma Collaboration	CI
Apr. 13	Regeneron, Telix Enter Radiopharma Collaboration; Telix Shares Up Pre-Bell	MT
Apr. 13	Sanofi, Regeneron's Dupixent Becomes First Targeted Treatment for Pediatric Chronic Spontaneous Urticaria in EU	MT
Apr. 13	Sanofi and Regeneron's Dupixent Approves in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria	CI
Apr. 13	Regeneron Pharmaceuticals, Sanofi's Dupixent Recieves EU Approval for Childhood Chronic Hives Treatment	MT
Apr. 13	Regeneron Pharmaceuticals, Inc. and Sanofi Receive European Commission Approval for Dupixent to Treat Chronic Spontaneous Urticaria in Children Aged 2 to 11 Years	CI
Apr. 13	Sanofi, Regeneron Win EU Approval for Chronic Spontaneous Urticaria Treatment in Children	MT
Apr. 12	Telix and Regeneron announce radiopharma collaboration	RE
Apr. 12	Telix Pharmaceuticals, Regeneron Form Radiopharmaceutical Partnership	MT
Apr. 08	Regeneron Expects $0.81 per Share Net Income Impact From $102 Million R&D Charges for Q1	MT
Apr. 02	Regeneron Taps TriNetX for Health Records of 300 Million Patients to Boost Research	MT
Apr. 02	Eylea HD approved by FDA as first and only injectable anti-VEGF with dosing intervals up to 5 months	RE
Apr. 02	Regeneron Pharmaceuticals Announces Eylea Hd Approval for Extended Dosing Intervals in Wet Age-Related Macular Degeneration and Diabetic Macular Edema	CI
Apr. 02	Regeneron Pharmaceuticals, Inc. Announces That the U.S. Food and Drug Administration Approves the Extension of Dosing Intervals for Eylea Hd	CI
Apr. 01	JPMorgan American Investment Trust lags benchmark but lifts payout	AN
Mar. 29	China's Hansoh Pharmaceutical Group beats net profit expectations in 2025	RE
Mar. 27	AstraZeneca drug reduces flare-ups of chronic lung disease in late-stage trials	RE
Mar. 24	Regeneron Pharmaceuticals, Inc. and Sanofi Approve Dupixent for Treatment of Adults with Bullous Pemphigoid in Japan	CI
Mar. 24	Japan Clears Sanofi, Regeneron's Dupixent as First Targeted Therapy for Rare Skin Disease	MT
Mar. 24	Sanofi, Regeneron Win Japanese Regulatory Nod for Skin Disease Treatment in Adults	MT
Mar. 23	Kali Therapeutics signs deal with Sanofi to develop autoimmune treatment	RE
Mar. 23	Cencora buys EyeSouth's retina business in $1.1 billion deal	RE
Mar. 23	Bayer Scores Regulatory Wins in Japan for Eylea Third Indication, MRI Contrast Agent	MT
Mar. 23	Bayer Wins Japanese Regulatory Approval for Higher Dose of Macular Edema Drug	MT
Mar. 19	Formycon Enters Licensing Deal for Eylea Biosimilars	MT